Cross-Protective Efficacy And Prevention Of Precancerous Vaginal Lesions Added To Gardasil(R) I Product Information
The product information of the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® has been updated to include cross-protective efficacy in preventing precancerous cervical lesions (CIN2/3 and AISiii) due to additional cancercausing HPV types related to HPV type 16.1 Statistically significant efficacy against disease was demonstrated against HPV 31 which is the second most common HPV type in Europe in causing precancerous cervical lesions, after type 16.
